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Keeping in mind that the beneﬁts were measured by sur-
vival groups, the cost effectiveness was: €57/month of life
for G1, 181 for G2, and 222 for G3. CONCLUSIONS:
not having an adequate vascular access in order to start
PHD, causes not only an important decrease of survival
but more indirect costs as less beneﬁt too.
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OBJECTIVES: The costs associated with kidney trans-
plantation are substantial, not only because of trans-
plantation surgery but also due to the life-long need for
immunosuppressive medication to prevent graft rejection.
We analyzed the clinical and economic consequences 
of the use of the two baseline immunosuppressants,
tacrolimus (Tac), and cyclosporin (CyA), currently
administered in clinical practice. METHODS: A retro-
spective economic analysis was performed from a hospi-
tal perspective in Italy, Spain, and Germany. The analysis
was conducted on the ITT-population comprising 557
patients from 7 European countries. Thus, the clinical and
medical resource information for the pharmacoeconomic
analysis was pooled multi-country data, the cost data was
country speciﬁc. Costs were calculated on the actual
resources used by each patient and assigned to the treat-
ment group to which the patient was randomized. Direct
medical resource use data was costed over 6 months post
transplantation. A local health economist collected cost
information from published sources and personal inter-
views with clinicians. Costs were collected on study drug,
concomitant medication, hospitalization, dialysis, and
rejection episodes. To explore the impact of any variabil-
ity of costs, a one-way sensitivity analysis was conducted.
RESULTS: Six months after transplantation, patient sur-
vival was 99.3% (Tac) and 98.5% (CyA), p = 0.366; graft
survival was 94.6% (Tac) and 91.9% (CyA), p = 0.139.
The incidence of acute graft rejection was 32.5% (Tac)
and 51.3% (CyA), p < 0.0001. Cost-minimization analy-
sis revealed savings for tacrolimus (per patient) of
€583–1874 for surviving patients, and €781–2305 for
patients with functioning grafts. Tacrolimus was cost-
effective for patients with rejection-free grafts; savings per
patient were €4627–9919. The tacrolimus group consis-
tently had lower total costs than the cyclosporin group.
The cost advantages for tacrolimus were a result of lower
overall hospitalization costs and lower incidences of dial-
ysis and graft rejection. A sensitivity analysis regarding
the main cost drivers (hospitalization, study drug, and
concomitant medication) generally conﬁrmed the robust-
ness of this ﬁnding in all 3 countries.
URINARY/KIDNEY DISEASES OR DISORDERS—
Quality of Life Studies
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OBJECTIVE: Use of electronic data capture (EDC) in the
assessment of patient status is increasing, however it must
be determined how data collected electronically correlates
with similar data collected using the standard “paper”
method. Our objective was to compare paper and elec-
tronic administrations of a urinary voiding and symptom
diary for use in a population with benign prostatic hyper-
plasia (BPH). METHODS: Using a crossover design, men
aged 45–85 with a diagnosis of BPH and IPSS scores of
8 or greater were recruited from clinics. Subjects com-
pleted either the paper or electronic version of the diary
(depending on randomized arm) for 7 consecutive days
and then the opposing version for the following 7 con-
secutive days. Data quality was assessed for both ver-
sions. Intraclass correlation coefﬁcients (ICC) and t-test
comparisons were calculated to compare EDC and paper
versions for the mean number of urinary events, symp-
toms, and severity of urgency. Ease of use, preference, and
demographic items were also collected. RESULTS: A total
of 28 subjects were assessed with 14 in each group. Mean
age and IPSS for the total sample was 63.8 and 17.3,
respectively. Data quality concerns were minimal with
both versions. Mean differences in urinary events, symp-
toms and severity were not signiﬁcantly different (p-
values > 0.29, ICC > 0.70). Participants who took the
electronic version ﬁrst thought the paper version was con-
siderably less convenient to keep with them and more dif-
ﬁcult to use. The majority of the sample (64%) would
prefer, if given a choice, the computerized version of the
diary compared with 29% opting for the paper version
(7% indicated no real preference for either). CONCLU-
SION: As in previous studies comparing electronic to
paper assessments, this study revealed statistical evidence
to support the use of EDC of a patient urinary diary.
While some difﬁculties existed, the electronic version pro-
duced good data with low data management burden.
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